Reference 2018-302

REF:           2018-302

Subject:       Biologics and Biosimilar prescribing

 

 

Request:

I have a Freedom of Information request regarding Biologics and Biosimilar prescribing.  Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for Rheumatology, Dermatology or Gastroenterology departments.

Number of patients treated Rheumatology Dermatology Gastroenterology
TOTAL      
Abatacept [Orencia]      
Adalimumab [Biosimilar]      
Adalimumab [Humira]      
Apremilast [Otezla]      
Baricitinib [Olumiant]      
Brodalumab [Kyntheum]      
Certolizumab [Cimzia]      
Dimethyl fumarate [Skilarence]      
Etanercept [Enbrel]      
Etanercept Biosimilar [Benepali or Erelzi]      
Golimumab [Simponi]      
Guselkumab [Tremfya]      
Infliximab [Remicade]      
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]      
Ixekizumab [Taltz]      
Rituximab [Mabthera]      
Rituximab Biosimilar [Rixathon or Truxima]      
Sarilumab [Kevzara]      
Secukinumab [Cosentyx]      
Tocilizumab [Ro Actemra]      
Tofacitinib [Xeljanz]      
Ustekinumab [Stelara]      
Vedolizumab [Entyvio]      

 

 

Response:

Under Section 21 Information already accesible

 

This exemption applies if the information requested is already accessible to the requester. You could apply this if you know that the requester already has the information, or if it is already in the public domain.

 

Please follow the link to an old response:

http://www.boltonft.nhs.uk/reference-2017-705/